MPH Health Care AG

Germany / Healthcare Frankfurt Bloomberg: 93M1 GR ISIN: DE000A289V03

H1 results

RATING	BUY
PRICE TARGET	€ 58.00
Return Potential	506.7%
Risk Rating	High

NAV HIT IN MARKET DOWNDRAFT

Six month reporting reflected the poor share price performances of the two listed holdings through the end of June. CR Capital AG shares slumped 10%, while M1 Kliniken stock fell some 31% during H1/22. This triggered a 19% H1 decline in the MPH NAVPS to €36.5. Despite the disappointing stock performances, operations at M1 and CR Capital have remained resilient YTD. M1 reported good treatment numbers in H1, while CRC delivered strong H1 results and rewarded shareholders with an upped dividend payout. We maintain our Buy rating but lower our TP to €58 (old: €67) to account for updated valuation models for M1 and CR Capital.

CR Capital developments The investment holding reported six month EBITDA of \in 67.7m vs \in 62.4m in the prior year period (+8.5%) with net income approaching \in 67m (H1/21: \in 62m). The performance owes mainly to Terrabau GmbH holding, which secured the needed materials and hands for the upcoming projects through 2023, whereas many rivals are handcuffed by material and labour shortages as well as rising interest rates. CRC announced two investments in sustainable technologies in Q1 including an 80% stake in Solartec GmbH. The company operates as a system integrator specialising in rooftop solar rigs combined with hydrogen technology to allow homeowners to store excess electricity produced during the sunshine months for winter usage.

M1 Kliniken developments M1 has opened five new clinics YTD with a further two centres slated for the fall. The company reported EBITDA of \in 7.6m, which translated into \in 10.2m in operating cash flow for the period. The Beauty segment contributed \in 2.6m to the group EBIT result, while Trade (Haemato) added \in 1.9m. We recently lowered our Trade targets to account for building regulatory headwinds faced by Haemato's Specialty Pharma business but left Beauty estimates unchanged. Despite tightening household budgets, we reckon most patients will not want to compromise their appearance by skipping treatments to save a few bucks next year. (p.t.o.)

FINANCIAL HISTORY & PROJECTIONS

	2018	2019	2020	2021	2022E	2023E
Operating rev. (€m)	39.53	41.22	3.43	13.55	13.93	28.49
Y/Y growth	0.2%	0.0%	-0.9%	2.9%	0.0%	1.0%
EBIT (€m)	37.64	11.58	-71.02	-9.07	-28.89	24.09
EBT (€m)	37.3%	11.0%	-71.5%	-9.2%	-28.9%	24.1%
Net income (€m)	37.03	11.08	-70.38	-8.96	-28.31	23.61
EPS (diluted) (€)	8.65	2.59	-16.44	-2.09	-6.61	5.51
DPS (€)	2.00	0.00	0.00	0.00	0.00	1.60
NAVPS (€)	62.87	63.45	47.01	44.92	38.30	43.82
Net gearing	4.8%	6.1%	1.7%	-0.2%	-3.9%	-6.2%
Liquid assets (€m)	1.02	1.80	0.37	1.84	3.79	8.98

RISKS

Regulatory changes in healthcare systems, homogenization of pharmaceutical prices within the EU, and prolonged macro economic downturns that limit private healthcare spend.

COMPANY PROFILE

MPH Health Care AG is a Berlin-based investment company focused on the purchase and further development of companies positioned chiefly in growth segments of the healthcare market. These primarily entail specialty pharmaceuticals for chronic diseases and lifestyle and beauty treatments. The company also holds a stake in a residential property developer.

MARKET DA	ТА	As of 0	3 Oct 2022
Closing Price			€ 9.56
Shares outstand	ding		4.28m
Market Capitalis	sation	\$	€ 40.93m
52-week Range	•	€ 9.4	0 / 25.60
Avg. Volume (1	2 Months)		2,182
Multiples	2021	2022E	2023E
P/E	n.a.	n.a.	1.7
EV/EBIT	0.0	0.0	1.8
P/NAV	0.2	0.2	0.2
Div. Yield	0.0%	0.0%	16.7%

STOCK OVERVIEW



COMPANY DATA	As of 30 Jun 2022
Liquid Assets	€ 1.49m
Current Assets	€ 4.23m
Financial Assets	€ 157.17m
Total Assets	€ 161.43m
Current Liabilities	€ 4.18m
Shareholders' Equity	€ 156.31m
SHAREHOLDERS	
Magnum	60.0%
Baring Fund Managers	1.7%
KBC Asset Management SA	1.3%
Free Float	37.0%

M1 KLINIKEN SIX MONTH REPORTING

Group revenue 16% lower Y/Y This owes to the absence of non-recurring antigen test kit sales (~25m) that inflated Haemato's H1/21 performance. Adjusted for the €25m in one-off sales, group revenue was in line with the prior year comp. H1/22 EBITDA tallied €7.4m but undershot the prior year figure by 24%, due to missing test kit sales.

In EURm	Q2/22	Q2/22E	Variance	Q2/21	Variance	H1/22	H1/21	Variance
Sales	75.2	74.3	1%	84.2	-11%	138.7	165.0	-16%
EBITDA	3.2	3.6	-11%	5.9	-46%	7.4	9.9	-25%
Margin	4.3%	4.8%	-	5.9%	-	5.3%	6.0%	-
EBIT	1.7	1.9	-11%	4.5	-62%	4.5	7.1	-37%
Margin	2.3%	2.6%	-	3.9%	-	3.2%	4.3%	-

Table 1: Second quarter vs FBe and prior year

Source: First Berlin Equity Research; M1 Kliniken

Beauty segment turnover up 16% year over year The \in 27.9m notched in H1/22 was spearheaded by a 32% increase in international clinic turnover. Beauty EBIT fell some 12%, due chiefly to the performance of the international component that includes high start-up costs for the new facilities. Treatment figures totalled 190k in H1 vs 163k in the prior year period led by a 50% rise across international centres with the UK in particular prospering from an aggressive pricing strategy. Germany notched a 10% Y/Y increase in treatments. As we wrote in our last M1 update (18 August 2022), we believe the Beauty business will remain resilient despite the impact of mounting economic turbulence on household wallets.

Table 2: Six month Beauty segment performance

	Н	1/22	Н	1/21	Var	iance
In EURm	Germany	International	Germany	International	Germany	International
Sales	24.0	3.8	21.1	2.9	14%	32%
EBIT	3.7	-1.2	3.3	-0.4	14%	n.m.
Margin	16%	-30%	16%	-12%	-	-

Source: First Berlin Equity Research; M1 Kliniken

Haemato shows good profitability The Lifestyle & Aesthetics (L&A) segment led Haemato's H1/22 profitability contributing a 29% gross margin (GM) on \in 24m in turnover for the period. Meanwhile, the optimised Specialty Pharma portfolio helped boost segment GM to 6.1% for the reporting period. This is a vast improvement over the ~4% GM normally booked by this business. Specialty Pharma turnover tallied \in 97m for the period.

L&A chiefly markets self-payer products for use in aesthetic medicine and for treatments but also includes diagnostic and Corona prevention products. Last year, Haemato recorded some €25m in antigen test kit sales at a 33.7% GM, but changing market conditions meant that this performance could not be repeated.

Table 3: Segment breakdown of Haemato (Trade) perf	ormance
--	--------	---------

EURm	Specialty Pharma	Lifestyle & Aesthetics
Revenue	97.1	23.9
Gross profit	5.9	6.2
Margin	6.1%	26.1%

Source: First Berlin Equity Research; Haemato AG

CR CAPITAL DEVELOPMENTS

Strong start to the year Six month results (table 4) were close to FBe. Portfolio revaluations accounted for the bulk of the \in 69m in investment revenue, which flowed abundantly to the bottom line, thanks to low operating costs and no interest expense. Net income tallied \in 67m for the period topping the prior year total (\in 62m). CRC also rewarded investors with a hefty increase in its dividend to \in 2.5 per share dividend (2020: \in 1.5ps; +67%), thanks to the good 2021 earnings performance.


All figures in EUR '000	H1/22	H1/22E	Variance	H1/21	Variance
Investment revenue	68,997	67,500	2.2%	63,688	8.3%
EBITDA	67,708	66,146	2.4%	62,447	8.4%
Margin (%)	98%	98%	-	98%	-
Net income	66,796	65,347	2.2%	61,636	8.4%
EPS diluted (€)	16.5	16.2	2.2%	16.5	0.3%

Table 4: Six month results vs prior year and FB	Table 4:	Six month	results vs	prior v	year and	FBe
---	----------	-----------	------------	---------	----------	-----

Climate neutral electrification solutions Meanwhile, earlier this year, CR Capital took an 80% stake in Solartec GmbH. The company designs and installs climate-neutral energy systems, which combine rooftop solar PV rigs with hydrogen technology for year-round electrification of private homes.

The green-home boom is gaining steam, thanks to rising energy prices, new green commitments by policy makers, and improved technologies. Many of these technologies have been around for a while, but they are now ready for mainstream applications. The case for homeowners to put solar panels on their roofs looks increasingly compelling because: (1) panels do not belch carbon dioxide; (2) electricity is generated where it is consumed and can ease the strain on transmission lines and power plants; and (3) the average price of residential solar systems is less than half its level in 2010.

Figure 1: Grid independence for homeowners



Source: First Berlin Equity Research; CR Capital

The rub with solar panels is they provide too much electricity in the summer and too little in wintertime, while efficient and / or economically feasible storage solutions are hard to come by. Solartec wants to solve this problem with electrolysers to produce clean hydrogen made by solar energy and with intelligent energy management systems.

Solartec contends that the pairing of solar panels with electrolysers can make homeowners grid-independent by converting surplus power produced by solar in the sunny summer months into hydrogen and storing it for winter usage rather than selling it back to utilities.

Clean hydrogen Currently, most hydrogen is produced from fossil fuels, specifically natural gas, that emit a lot of CO_2 unless coupled with technologies that capture and sequester carbon. The cleaner way is to use zero-carbon electricity to run electrolysers that split water into hydrogen and oxygen. But this is a power-hungry process—50 to 60 kWh are required for every kilogram of hydrogen produced.

Figure 2: Electrolyser technology for clean hydrogen



Source: First Berlin Equity Research; Enapter S.r.l.

Solar can substitute for dirty fossil fuels to produce green hydrogen in two ways. The first is via a photochemical process that uses solar energy directly to split water into hydrogen and O_2 . While direct hydrogen production is attractive, the method must still undergo significant innovation to reach scalability.

The second is solar powered electrolysis, which uses solar cells to generate electricity and tear water molecules apart, thereby liberating their constituent hydrogen and oxygen. Given the reliance on established technologies, this method is better suited to produce sufficient amounts of green hydrogen in sunny regions.

Putting it all together Solartec will source solar panels from US and German manufacturers and avoid dependency on Chinese modules. Large order volumes should mitigate delivery issues. The company also has an agreement in place with a German maker of electrolysers—the key component for year round electrification solutions.

Solartec will work closely with Terrabau GmbH and plans to connect multiple homes to a single system to divvy up the investment costs among multiple homeowners. Aside from the residential business, Solartec plans to roll out a B2B model to commercial landlords. The company reckons these channels will lead to a €20m market opportunity over the near term. With key components secured and a ready-made customer in Terrabau, we think Solartec should have a strong operational start. The system integrator recently completed realising its first pilot project in Ludwigsfelde.

MPH SIX MONTH RESULT HIGHLIGHTS

NAVPS down 19% YTD NAV declined to \in 156m (YE21: \in 192m) at the 6M mark corresponding to NAVPS of \in 36.5. The performance owes to \in -36.0m in net income traced primarily to non-cash fair value write-downs of \in -36.3m plus \in 0.3m in profit from the net sales of participations.





Source: First Berlin Equity Research; MPH Health Care AG

The weak portfolio showing owes mainly to the retreat in the M1 share price, which has tumbled some 41% YTD on recession worries. However, we reckon most patients will not want to compromise their public appearance—anti-aging effects from injectables stop if treatments are skipped—to save a few bucks.

Women in particular prioritise their beauty regimens and will generally make their budgets fit—even it means turning the heat down over the winter. Injectable treatments are really quite affordable (especially at M1) at roughly \in 100 to \in 150 every 4-6 months. German households are also flush with cash after having socked away >15% of their earnings the past two years with fewer options to splurge.

Table 5: MPH Financial highlights

00			
All figures in EUR '000	H1/22	2021	variance
Cash	1,495	1,843	-19%
Financial assets	157,169	193,502	-19%
Financial debt (short- and long-term)	4,031	4,028	0%
Net debt	2,536	2,185	16%
Total assets	161,430	197,996	-18%
Shareholders' equity	156,312	192,306	-19%
Equity ratio	97%	97%	-
NAV	156,312	192,306	-19%
NAVPS (€)	36.5	44.9	-19%

Source: First Berlin Equity Research; MPH Health Care AG

VALUATION MODEL

We use a sum-of-the-parts valuation methodology to value MPH. Value is driven by the projected fair value of M1 Kliniken and CR Capital, which we have valued separately on a DCF and DDM basis (overleaf). Shareholdings reflect six month reporting.

Table 6: MPH SotP model

	Shareholdings	SO	MPH stake	Share price*	Fair value per share¹	Projected value
Unit	'000	'000	%	€	€	€m
M1 Kliniken AG	12,241	19,643	62%	3.9	11.7	143
CR Capital Real Estate AG	2,328	4,051	57%	24.3	53.0	123
Haemato AG	12	5,229	0.2%	13.9	35.0	0.4
Projected value of listed holding	gs					267
* Source: Bloomberg (Previous day's closing pr	ice)					
	Unit	Value				
Fair value of listed portfolio	€m	267				
Non-listed investment (book value)	€m	24				
Net debt (2021)	€m	0				
Present value of holding costs	€m	43				
Total fair value	€m	248				
MPH shares outstanding	m	4				
Fair value per share	€	58				

¹ First Berlin Equity Research covers CR Capital (Buy / PT: €53); M 1 (Buy / PT: €11.7); HAE (Buy / PT: €35)

	Unit	New	Old	Variance
Fair value of listed portfolio	€m	267	306	-13%
Non-listed investment (book value)	€m	24	24	0%
Net debt	€m	0	0	-
Present value of holding costs	€m	43	43	-1%
Total fair value	€m	248	287	-14%
MPH shares outstanding	m	4	4	0%
Fair value per share	€	58	67	-13%

Source: First Berlin Equity Research estimates

We recently revised our M1 Kliniken forecasts to reflect pricing pressure from health insurance funds and manufacturers impacting Haemato's insurance-financed Specialty Pharma operations that are booked in M1's Trade segment. This results in fair value / share of \in 11.7 (old: \in 14) for M1.

Table 7: M1 Kliniken DCF

All figures in EUR '000	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E
Sales	286,507	315,088	351,703	387,362	418,791	444,738	463,104	477,275
NOPLAT	7,918	9,830	13,516	18,305	22,175	26,073	29,049	30,743
(+) depreciation & amortisation	6,560	7,084	8,234	8,049	8,188	7,955	7,117	6,992
(=) Net operating cash flow	14,478	16,914	21,750	26,355	30,363	34,027	36,165	37,735
(-) Total investments (CapEx and WC)	-911	-11,437	-12,700	-12,097	-11,716	-10,392	-10,061	-9,691
(-) Capital expenditures	-7,782	-8,417	-9,287	-8,792	-8,712	-7,916	-8,174	-8,225
(-) Working capital	6,871	-3,019	-3,414	-3,305	-3,004	-2,477	-1,887	-1,466
(=) Free cash flows (FCF)	13,567	5,477	9,050	14,258	18,647	23,635	26,104	28,044
PV of FCF's	13,243	4,836	7,228	10,300	12,185	13,970	13,957	13,563

						Term inal E	BIT margin			
All figures in EUR '000				6.7%	7.2%	7.7%	8.2%	8.7%	9.2%	9.7%
PV of FCFs in explicit period	135,996		7.5%	16.60	17.67	18.75	19.82	20.90	21.97	23.04
PV of FCFs in terminal period	120,983	o	8.5%	13.83	14.65	15.47	16.29	17.11	17.93	18.75
Enterprise value (EV)	256,979	AC	9.5%	11.79	12.43	13.07	13.72	14.36	15.00	15.64
+ Net cash / - net debt	15,061	>	10.5%	10.22	10.73	11.24	11.75	12.26	12.78	13.29
+ Investments / minority interests	-41,497		11.5%	8.97	9.38	9.80	10.21	10.62	11.04	11.45
Shareholder value	230,543		12.5%	7.95	8.29	8.63	8.97	9.31	9.65	9.99
Fair value per share in EUR	11.70		13.5%	7.11	7.39	7.67	7.95	8.23	8.51	8.79
						Term inal g	grow th rate			
				0.5%	1.0%	1.5%	2.0%	2.5%	3.0%	3.5%
Cost of equity	11.4%		7.5%	16.91	17.73	18.69	19.82	21.18	22.83	24.89
Pre-tax cost of debt	4.5%		8.5%	14.33	14.90	15.55	16.29	17.17	18.19	19.43
Tax rate	25.0%	8	9.5%	12.34	12.74	13.20	13.72	14.31	14.99	15.78
After-tax cost of debt	3.4%	₹.	10.5%	10.75	11.05	11.38	11.75	12.17	12.64	13.18
Share of equity capital	90.0%	-	11.5%	9.47	9.69	9.94	10.21	10.51	10.85	11.23
Share of debt capital	10.0%		12.5%	8.41	8.58	8.77	8.97	9.19	9.44	9.72
WACC	10.6%		13.5%	7.52	7.65	7.80	7.95	8.12	8.31	8.51

*Please note our model runs through 2030 and we have only shown the abbreviated version for formatting purposes

Meanwhile, our target price for CR Capital is now \in 53 (old: \in 58) after rolling our model forward and factoring in the scrip dividend dilutive effects from 2021 earnings. The combined changes point to a \in 58 target price for MPH (old: \in 67). Our rating remains Buy.

Table 8: CR Capital discounted dividend model

	Unit	2022E	2023E	2024E	2025E	2026E	2027E	2028E	т٧
EPS	€	17.0	17.0	19.1	21.1	23.2	25.1	26.4	30.1
Payout ratio	%	15	16	15	15	15	15	15	15
Dividend (DPS)	€	2.6	2.7	2.9	3.2	3.5	3.8	4.0	4.5
Y/Y	%	4.0	3.8	7.4	10.3	9.4	8.6	5.3	-
NPV	€	2.5	2.4	2.4	2.4	2.4	2.4	2.4	26.0
CAGR 2022 - 2026	%	7.0							
Terminal grow th rate	%	2.0							
Discount factor	%	8.8							
NPV of dividends	€	27							
Terminal value (TV)	€	26							
Fair value per share	€	53.0							

*Our model runs through 2033 and we have only shown the abbreviated version for formatting purposes

Cost of equity	8.8%	After-tax cost of debt	4.9%
Pre-tax cost of debt	5.0%	Share of equity capital	100.0%
Tax rate	2.0%	Share of debt capital	0.0%
WACC	8.8%		

INCOME STATEMENT

All figures in EUR '000	2018	2019	2020	2021	2022E	2023E
Fair value gains on financial assets	31,019	33,747	0	9,185	9,675	23,877
Income from participations	170	780	0	766	400	400
Investment income	8,317	6,651	3,385	3,561	3,820	4,175
Other operating income	28	43	48	35	37	38
Operating revenue	39,534	41,221	3,433	13,547	13,932	28,490
SG&A	-1,146	-934	-841	-923	-969	-1,018
Other OpEx	-703	-330	-417	-328	-344	-362
Net loss from investments	0	-1,164	-12,453	0	0	0
Fair value loss on financial assets	0	-27,207	-60,720	-21,350	-41,500	-3,000
Depreciation & amortisation	-45	-11	-17	-20	-7	-18
EBIT	37,640	11,575	-71,015	-9,075	-28,889	24,093
Interest expense	-507	-540	-510	-194	0	0
Interest income	209	15	75	80	0	0
EBT	37,342	11,050	-71,450	-9,189	-28,889	24,093
Income taxes	-317	27	1,071	233	578	-482
Net income / loss	37,025	11,076	-70,379	-8,956	-28,311	23,611
Minority interests	0	0	0	0	0	0
Net income after minorities	37,025	11,076	-70,379	-8,956	-28,311	23,611
EPS (in €)	8.6	2.6	-16.4	-2.1	-6.6	5.5

BALANCE SHEET

All figures in EUR '000	2018	2019	2020	2021	2022E	2023E
Assets						
Current assets, total	1,152	2,237	4,318	4,453	6,449	11,694
Cash and equivalents	1,018	1,797	369	1,843	3,786	8,977
ST financial assets	64	305	3,865	2,599	2,651	2,704
Trade receivables	3	4	0	0	0	0
Inventories	7	0	0	0	0	0
Other ST assets	60	131	84	11	12	13
Non-current assets, total	285,101	290,908	206,390	193,543	159,219	177,597
Property, plant & equipment	2	56	43	41	42	43
Goodw ill & other intangibles	1	1	0	0	0	0
Financial assets	285,098	290,851	206,346	193,502	159,177	177,554
Total assets	286,253	293,144	210,707	197,996	165,668	189, 290
Shareholders' equity & debt						
Current liabilities, total	327	15,724	4,742	4,200	176	180
Trade payables	28	24	36	51	51	51
Provisions	99	91	74	101	104	107
Other ST financial liabilities	87	15,578	4,613	4,028	0	0
Other current liabilities	113	31	19	20	21	22
Long-term liabilities, total	16,798	5,779	4,703	1,490	1,497	1,504
Long-term debt	14,000	3,000	3,000	0	0	0
Deferred tax liabilities & others	2,798	2,779	1,703	1,490	1,497	1,504
Shareholders' equity	269,127	271,641	201,262	192,306	163,995	187,606
Minority interests	0	0	0	0	0	0
Total equity	269,128	271,641	201,262	192,306	163,995	187,606
Total consolidated equity and debt	286,253	293,144	210,707	197,996	165,668	189,290
NAV	269,128	271,641	201,262	192,306	163,995	187,606
NAVPS (€)	62.9	63.5	47.0	44.9	38.3	43.8

CASH FLOW STATEMENT

All figures in EUR '000	2018	2019	2020	2021	2022E	2023E
Net income	37,025	11,076	-70,379	-8,956	-28,311	23,611
Depreciation and amortisation	45	11	17	20	7	18
Revaluation gains	-30,360	-6,540	60,720	12,165	31,825	-20,877
Changes in w orking capital	7,058	-93	-3,581	1,619	-42	-43
Other adjustments	-830	384	12,453	-761	0	0
Net financial result	299	526	510	195	0	0
Tax expense	317	-26	-1,071	-233	-578	482
Operating cash flow	13,554	5,337	-1,331	4,049	2,901	3,191
Investment income	-8,317	-6,651	-1,500	-5,173	-3,820	-4,175
Tax paid	-41	-38	41	38	578	-482
Net operating cash flow	5,196	-1,352	-2,790	-1,086	-341	-1,465
СарЕх	-11	-52	-4	-2	-8	-19
Payments from acquistions of consildated companies & other business units	0	1,856	0	0	0	0
Proceeds from disposal of fixed assets	11,783	17,661	11,332	6,248	2,500	2,500
Payments for investment in financial assets	-16,644	-19,116	0	-4,780	0	0
Investment income	8,317	6,378	1,500	4,901	3,820	4,175
Interest income	208	15	0	0	0	0
Cash flow from investing	3,653	6,742	12,828	6,366	6,312	6,656
Equity inflow , net	0	-1	-4	0	0	0
Debt inflow, net	0	4,492	-11,000	-12	-4,028	0
Dividend paid to shareholders	-8,563	-8,562	0	0	0	0
Interest expense	-507	-540	-462	-194	0	0
Cash flow from financing	-9,070	-4,611	-11,466	-206	-4,028	0
Liabilities due at beginning of the period	0	0	0	-3,600	0	0
Net cash flows	-221	779	-1,428	5,075	1,943	5,190
Cash, start of the year	1,239	1,018	1,797	369	1,843	3,786
Cash, end of the year	1,018	1,797	369	1,843	3,786	8,977
Free cash flow (FCF)	8,849	5,390	10,038	5,280	5,971	5,190
Y-Y Growth						
Operating cash flow	415.0%	n.m.	n.m.	n.m.	n.m.	n.m.
Free cash flow	50.2%	-39.1%	86.2%	-47.4%	13.1%	-13.1%

Imprint / Disclaimer

First Berlin Equity Research

First Berlin Equity Research GmbH ist ein von der BaFin betreffend die Einhaltung der Pflichten des §85 Abs. 1 S. 1 WpHG, des Art. 20 Abs. 1 Marktmissbrauchsverordnung (MAR) und der Markets Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Durchführungsverordnung und der Markets in Financial Instruments Regulations (MiFIR) beaufsichtigtes Unternehmen.

First Berlin Equity Research GmbH is one of the companies monitored by BaFin with regard to its compliance with the requirements of Section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) Market Abuse Regulation (MAR) and Markets in Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Commission Delegated Regulation and Markets in Financial Instruments Regulations (MiFIR).

Anschrift: First Berlin Equity Research GmbH Mohrenstr. 34 10117 Berlin Germany

Vertreten durch den Geschäftsführer: Martin Bailey

Telefon: +49 (0) 30-80 93 9 680 Fax: +49 (0) 30-80 93 9 687 E-Mail: <u>info@firstberlin.com</u>

Amtsgericht Berlin Charlottenburg HR B 103329 B UST-Id.: 251601797 Ggf. Inhaltlich Verantwortlicher gem. § 6 MDStV First Berlin Equity Research GmbH

Authored by: Ellis Acklin, Senior Analyst All publications of the last 12 months were authored by Ellis Acklin.

Company responsible for preparation: First Berlin Equity Research GmbH, Mohrenstraße 34, 10117 Berlin

The production of this recommendation was completed on 4 October 2022 at 12:45

Person responsible for forwarding or distributing this financial analysis: Martin Bailey

Copyright 2022 First Berlin Equity Research GmbH No part of this financial analysis may be copied, photocopied, duplicated or distributed in any form or media whatsoever without prior written permission from First Berlin Equity Research GmbH. First Berlin Equity Research GmbH shall be identified as the source in the case of quotations. Further information is available on request.

INFORMATION PURSUANT TO SECTION 85 (1) SENTENCE 1 OF THE GERMAN SECURITIES TRADING ACT [WPHG], TO ART. 20 (1) OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF APRIL 16, 2014, ON MARKET ABUSE (MARKET ABUSE REGULATION) AND TO ART. 37 OF COMMISSION DELEGATED REGULATION (EU) NO 2017/565 (MIFID) II.

First Berlin Equity Research GmbH (hereinafter referred to as: "First Berlin") prepares financial analyses while taking the relevant regulatory provisions, in particular section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) and art. 37 of Commission Delegated Regulation (EU) no. 2017/565 (MiFID II) into consideration. In the following First Berlin provides investors with information about the statutory provisions that are to be observed in the preparation of financial analyses.

CONFLICTS OF INTEREST

In accordance with art. 37 (1) of Commission Delegated Regulation (EU) no. 2017/565 (MiFID) II and art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) investment firms which produce, or arrange for the production of, investment research that is intended or likely to be subsequently disseminated to clients of the firm or to the public, under their own responsibility or that of a member of their group, shall ensure the implementation of all the measures set forth in accordance with Article 34 (2) lit. (b) of Regulation (EU) 2017/565 in relation to the financial analysts involved in the production of the investment research and other relevant persons whose responsibilities or business interests may conflict with the interests of the persons to whom the investment research is disseminated. In accordance with art. 34 (3) of Regulation (EU) 2017/565 the procedures and measures referred to in paragraph 2 lit. (b) of such article shall be designed to ensure that relevant persons engaged in different business activities involvies at level of independence appropriate to the size and activities of the investment firm and of the group to which it belongs, and to the risk of damage to the interests of clients.

In addition, First Berlin shall pursuant to Article 5 of the Commission Delegated Regulation (EU) 2016/958 disclose in their recommendations all relationships and circumstances that may reasonably be expected to impair the objectivity of the financial analyses, including interests or conflicts of interest, on their part or on the part of any natural or legal person working for them under a contract, including a contract of employment, or otherwise, who was involved in producing financial analyses, concerning any financial instrument or the issuer to which the recommendation directly or indirectly relates.

With regard to the financial analyses of MPH Health Care AG the following relationships and circumstances exist which may reasonably be expected to impair the objectivity of the financial analyses: The author, First Berlin, or a company associated with First Berlin reached an agreement with the MPH Health Care AG for preparation of a financial analysis for which remuneration is owed.

Furthermore, First Berlin offers a range of services that go beyond the preparation of financial analyses. Although First Berlin strives to avoid conflicts of interest wherever possible, First Berlin may maintain the following relations with the analysed company, which in particular may constitute a potential conflict of interest:

- The author, First Berlin, or a company associated with First Berlin owns a net long or short position exceeding the threshold of 0.5 % of the total issued share capital of the analysed company;
- The author, First Berlin, or a company associated with First Berlin holds an interest of more than five percent in the share capital of the analysed company;

- The author, First Berlin, or a company associated with First Berlin provided investment banking or consulting services for the analysed company within the past twelve months for which remuneration was or was to be paid;
- The author, First Berlin, or a company associated with First Berlin reached an agreement with the analysed company for preparation of a financial analysis for which remuneration is owed;
- The author, First Berlin, or a company associated with First Berlin has other significant financial interests in the analysed company;

With regard to the financial analyses of MPH Health Care AG the following of the aforementioned potential conflicts of interests or the potential conflicts of interest mentioned in Article 6 paragraph 1 of the Commission Delegated Regulation (EU) 2016/958 exist: The author, First Berlin, or a company associated with First Berlin reached an agreement with the MPH Health Care AG for preparation of a financial analysis for which remuneration is owed.

In order to avoid and, if necessary, manage possible conflicts of interest both the author of the financial analysis and First Berlin shall be obliged to neither hold nor in any way trade the securities of the company analyzed. The remuneration of the author of the financial analysis stands in no direct or indirect connection with the recommendations or opinions represented in the financial analysis. Furthermore, the remuneration of the author of the financial analysis is neither coupled directly to financial transactions nor to stock exchange trading volume or asset management fees.

INFORMATION PURSUANT TO SECTION 64 OF THE GERMAN SECURITIES TRADING ACT [WPHG], DIRECTIVE 2014/65/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 15 MAY 2014 ON MARKETS IN FINANCIAL INSTRUMENTS AND AMENDING DIRECTIVE 2002/92/EC AND DIRECTIVE 2011/61/EU, ACCOMPANIED BY THE MARKETS IN FINANCIAL INSTRUMENTS REGULATION (MIFIR, REG. EU NO. 600/2014).

First Berlin notes that is has concluded a contract with the issuer to prepare financial analyses and is paid for that by the issuer. First Berlin makes the financial analysis simultaneously available for all interested security financial services companies. First Berlin thus believes that it fulfils the requirements of section 64 WpHG for minor non-monetary benefits.

PRICE TARGET DATES

Unless otherwise indicated, current prices refer to the closing prices of the previous trading day.

AGREEMENT WITH THE ANALYSED COMPANY AND MAINTENANCE OF OBJECTIVITY

The present financial analysis is based on the author's own knowledge and research. The author prepared this study without any direct or indirect influence exerted on the part of the analysed company. Parts of the financial analysis were possibly provided to the analysed company prior to publication in order to avoid inaccuracies in the representation of facts. However, no substantial changes were made at the request of the analysed company following any such provision.

ASSET VALUATION SYSTEM

First Berlin's system for asset valuation is divided into an asset recommendation and a risk assessment.

ASSET RECOMMENDATION

The recommendations determined in accordance with the share price trend anticipated by First Berlin in the respectively indicated investment period are as follows:

Category			2
Current market	capitalisation (in €)	0 - 2 billion	> 2 billion
Strong Buy ¹	An expected favourable price trend of:	> 50%	> 30%
Buy	An expected favourable price trend of:	> 25%	> 15%
Add	An expected favourable price trend of:	0% to 25%	0% to 15%
Reduce	An expected negative price trend of:	0% to -15%	0% to -10%
Sell	An expected negative price trend of:	< -15%	< -10%

¹ The expected price trend is in combination with sizable confidence in the quality and forecast security of management

Our recommendation system places each company into one of two market capitalisation categories. Category 1 companies have a market capitalisation of $\leq 0 - \leq 2$ billion, and Category 2 companies have a market capitalisation of $> \leq 2$ billion. The expected return thresholds underlying our recommendation system are lower for Category 2 companies than for Category 1 companies. This reflects the generally lower level of risk associated with higher market capitalisation companies.

RISK ASSESSMENT

The First Berlin categories for risk assessment are low, average, high and speculative. They are determined by ten factors: Corporate governance, quality of earnings, management strength, balance sheet and financial risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, strength of brandname, market capitalisation and free float. These risk factors are incorporated into the First Berlin valuation models and are thus included in the target prices. First Berlin customers may request the models.

RECOMMENDATION & PRICE TARGET HISTORY

Report No.:	Date of publication	Previous day closing price	Recommendation	Price target
Initial Report	29 October 2012	€24.55	Buy	€55.00
220	Ļ	Ļ	Ļ	Ļ
21	16 September 2020	€26.00	Buy	€75.00
22	7 December 2020	€22.20	Buy	€75.00
23	6 May 2021	€27.40	Buy	€75.00
24	11 June 2021	€28.50	Buy	€75.00
25	20 September 2021	€23.30	Buy	€75.00
26	24 February 2022	€21.20	Buy	€67.00
27	2 May 2022	€22.30	Buy	€67.00
28	22 September 2022	€16.95	Buy	€67.00
29	Today	€9.56	Buy	€58.00

INVESTMENT HORIZON

Unless otherwise stated in the financial analysis, the ratings refer to an investment period of twelve months.

UPDATES

At the time of publication of this financial analysis it is not certain whether, when and on what occasion an update will be provided. In general First Berlin strives to review the financial analysis for its topicality and, if required, to update it in a very timely manner in connection with the reporting obligations of the analysed company or on the occasion of ad hoc notifications.

SUBJECT TO CHANGE

The opinions contained in the financial analysis reflect the assessment of the author on the day of publication of the financial analysis. The author of the financial analysis reserves the right to change such opinion without prior notification.

Legally required information regarding

- key sources of information in the preparation of this research report
- valuation methods and principles
- sensitivity of valuation parameters

can be accessed through the following internet link: https://firstberlin.com/disclaimer-english-link/

SUPERVISORY AUTHORITY: Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) [BaFin], Graurheindorferstraße 108, 53117 Bonn and Marie-Curie-Straße 24-28, 60439 Frankfurt am Main

EXCLUSION OF LIABILITY (DISCLAIMER)

RELIABILITY OF INFORMATION AND SOURCES OF INFORMATION

The information contained in this study is based on sources considered by the author to be reliable. Comprehensive verification of the accuracy and completeness of information and the reliability of sources of information has neither been carried out by the author nor by First Berlin. As a result no warranty of any kind whatsoever shall be assumed for the accuracy and completeness of information and the reliability of sources of information, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the accuracy and completeness of information and the reliability of sources of information.

RELIABILITY OF ESTIMATES AND FORECASTS

The author of the financial analysis made estimates and forecasts to the best of the author's knowledge. These estimates and forecasts reflect the author's personal opinion and judgement. The premises for estimates and forecasts as well as the author's perspective on such premises are subject to constant change. Expectations with regard to the future performance of a financial instrument are the result of a measurement at a single point in time and may change at any time. The result of a financial analysis always describes only one possible future development - the one that is most probable from the perspective of the author - of a number of possible future developments.

Any and all market values or target prices indicated for the company analysed in this financial analysis may not be achieved due to various risk factors, including but not limited to market volatility, sector volatility, the actions of the analysed company, economic climate, failure to achieve earnings and/or sales forecasts, unavailability of complete and precise information and/or a subsequently occurring event which affects the underlying assumptions of the author and/or other sources on which the author relies in this document. Past performance is not an indicator of future results; past values cannot be carried over into the future.

Consequently, no warranty of any kind whatsoever shall be assumed for the accuracy of estimates and forecasts, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the correctness of estimates and forecasts

INFORMATION PURPOSES, NO RECOMMENDATION, SOLICITATION, NO OFFER FOR THE

PURCHASE OF SECURITIES

The present financial analysis serves information purposes. It is intended to support institutional investors in making their own investment decisions; however in no way provide the investor with investment advice. Neither the author, nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be considered to be acting as an investment advisor or portfolio manager vis-à-vis an investor. Each investor must form his own independent opinion with regard to the suitability of an investment in view of his own investment objectives, experience, tax situation, financial position and other

The financial analysis does not represent a recommendation or solicitation and is not an offer for the purchase of the security specified in this financial analysis. Consequently, neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall as a result be liable for losses incurred through direct or indirect employment or use of any kind whatsoever of information or statements arising out of this financial analysis

A decision concerning an investment in securities should take place on the basis of independent investment analyses and procedures as well as other studies including, but not limited to, information memoranda, sales or issuing prospectuses and not on the basis of this document.

NO ESTABLISHMENT OF CONTRACTUAL OBLIGATIONS

By taking note of this financial analysis the recipient neither becomes a customer of First Berlin, nor does First Berlin incur any contractual, quasi-contractual or pre-contractual obligations and/or responsibilities toward the recipient. In particular no information contract shall be established between First Berlin and the recipient of this information.

NO OBLIGATION TO UPDATE

First Berlin, the author and/or the person responsible for passing on or distributing the financial analysis shall not be obliged to update the financial analysis. Investors must keep themselves informed about the current course of business and any changes in the current course of business of the analysed company.

Dispatch or duplication of this document is not permitted without the prior written consent of First Berlin.

SEVERABILITY

DUPLICATION

Should any provision of this disclaimer prove to be illegal, invalid or unenforceable under the respectively applicable law, then such provision shall be treated as if it were not an integral component of this disclaimer; in no way shall it affect the legality, validity or enforceability of the remaining provisions.

APPLICABLE LAW, PLACE OF JURISDICTION

The preparation of this financial analysis shall be subject to the law obtaining in the Federal Republic of Germany. The place of jurisdiction for any disputes shall be Berlin (Germany).

NOTICE OF DISCLAIMER

By taking note of this financial analysis the recipient confirms the binding nature of the above explanations.

By using this document or relying on it in any manner whatsoever the recipient accepts the above restrictions as binding for the recipient

QUALIFIED INSTITUTIONAL INVESTORS

First Berlin financial analyses are intended exclusively for qualified institutional investors.

This report is not intended for distribution in the USA and/or Canada.